To describe presymptomatic identification of neuronal ceroid lipofuscinosis type 2 (CLN2) through genome-based newborn screening and the confirmatory clinical, molecular, and biochemical evaluation that followed.
To describe presymptomatic identification of neuronal ceroid lipofuscinosis type 2 (CLN2) through genome-based newborn screening and the confirmatory clinical, molecular, and biochemical evaluation that followed.